Enjoy complimentary customisation on priority with our Enterprise License!
The motion sickness drugs market size is forecast to increase by USD 139.5 billion at a CAGR of 4.37% between 2023 and 2028. The market is experiencing significant growth due to the availability of over-the-counter (OTC) medications such as Meclizine and Diphenhydramine. Additionally, the advent of nauseogenic information technology in developed economies like the US and Saint Maarten is driving the market forward. Prescription drugs like Prochlorperazine and Scopolamine continue to dominate the market, providing effective relief for motion sickness. Nonpharmacological countermeasures, such as acupressure and ginger, are also gaining popularity as alternative treatments. The market is expected to continue its expansion, offering opportunities for both established players and new entrants.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.